Section Arrow
YARW.NASDAQ
- Yarrow Bioscience Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/08/02 08:10 EDT
Regular Hours
Last
 35.02
+2.03 (+6.15%)
Day High 
35.955 
Prev. Close
32.99 
1-M High
46.95 
Volume 
18.49K 
Bid
33.71
Ask
34.4
Day Low
31.55 
Open
34.79 
1-M Low
23.37 
Market Cap 
1.10B 
Currency 美元 
P/E -- 
%Yield 57.46 
10-SMA 35.96 
20-SMA 35.16 
50-SMA 33.89 
52-W High 46.95 
52-W Low 14.025 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-25.00/-0.64
Enterprise Value
1.10B
Balance Sheet
Book Value Per Share
36.90
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
570.00K
Operating Revenue Per Share
0.61
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.